1
|
Büchold C, Hils M, Gerlach U, Weber J, Pelzer C, Heil A, Aeschlimann D, Pasternack R. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells 2022; 11:cells11101667. [PMID: 35626704 PMCID: PMC9139979 DOI: 10.3390/cells11101667] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 05/12/2022] [Accepted: 05/14/2022] [Indexed: 02/04/2023] Open
Abstract
ZED1227 is a small molecule tissue transglutaminase (TG2) inhibitor. The compound selectively binds to the active state of TG2, forming a stable covalent bond with the cysteine in its catalytic center. The molecule was designed for the treatment of celiac disease. Celiac disease is an autoimmune-mediated chronic inflammatory condition of the small intestine affecting about 1–2% of people in Caucasian populations. The autoimmune disease is triggered by dietary gluten. Consumption of staple foods containing wheat, barley, or rye leads to destruction of the small intestinal mucosa in genetically susceptible individuals, and this is accompanied by the generation of characteristic TG2 autoantibodies. TG2 plays a causative role in the pathogenesis of celiac disease. Upon activation by Ca2+, it catalyzes the deamidation of gliadin peptides as well as the crosslinking of gliadin peptides to TG2 itself. These modified biological structures trigger breaking of oral tolerance to gluten, self-tolerance to TG2, and the activation of cytotoxic immune cells in the gut mucosa. Recently, in an exploratory proof-of-concept study, ZED1227 administration clinically validated TG2 as a “druggable” target in celiac disease. Here, we describe the specific features and profiling data of the drug candidate ZED1227. Further, we give an outlook on TG2 inhibition as a therapeutic approach in indications beyond celiac disease.
Collapse
Affiliation(s)
- Christian Büchold
- Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany; (C.B.); (M.H.); (J.W.); (C.P.); (A.H.)
| | - Martin Hils
- Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany; (C.B.); (M.H.); (J.W.); (C.P.); (A.H.)
| | - Uwe Gerlach
- Sanofi-Aventis Deutschland GmbH, UG Serves as External Consultant for Medicinal Chemistry to Zedira, 65926 Frankfurt, Germany;
| | - Johannes Weber
- Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany; (C.B.); (M.H.); (J.W.); (C.P.); (A.H.)
| | - Christiane Pelzer
- Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany; (C.B.); (M.H.); (J.W.); (C.P.); (A.H.)
| | - Andreas Heil
- Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany; (C.B.); (M.H.); (J.W.); (C.P.); (A.H.)
| | - Daniel Aeschlimann
- Matrix Biology & Tissue Repair Research Unit, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, Wales, UK;
| | - Ralf Pasternack
- Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany; (C.B.); (M.H.); (J.W.); (C.P.); (A.H.)
- Correspondence:
| |
Collapse
|
2
|
Deerberg J, Prasad SJ, Sfouggatakis C, Eastgate MD, Fan Y, Chidambaram R, Sharma P, Li L, Schild R, Müslehiddinoğlu J, Chung HJ, Leung S, Rosso V. Stereoselective Bulk Synthesis of CCR2 Antagonist BMS-741672: Assembly of an All-cis (S,R,R)-1,2,4-Triaminocyclohexane (TACH) Core via Sequential Heterogeneous Asymmetric Hydrogenations. Org Process Res Dev 2016. [DOI: 10.1021/acs.oprd.6b00282] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Joerg Deerberg
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Siva J. Prasad
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Chris Sfouggatakis
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Martin D. Eastgate
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Yu Fan
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Ramakrishnan Chidambaram
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Praveen Sharma
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Li Li
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Richard Schild
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Jale Müslehiddinoğlu
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Hyei-Jha Chung
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Simon Leung
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Victor Rosso
- Chemical and Synthetic
Development, Bristol-Myers
Squibb Company, One Squibb Drive, New Brunswick, New Jersey 08901, United States
| |
Collapse
|